Vicore Pharma: First Patient In – IPF
Research Note
2020-11-16
10:33
Redeye acknowledges a milestone with the first patient dosed in the phase II IPF trial. The timing is in line with our estimates and we anticipate data readout in H1 2022, subject to the corona situation.
LS
Ludvig Svensson
Disclosures and disclaimers